查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586052

癌症免疫疗法药物发现外包市场：按癌症类型、药物类型和服务类型 - 2025-2030 年全球预测

Cancer Immunotherapy Drug Discovery Outsourcing Market by Cancer Type (Breast, Colorectal, Head and Neck), Drug Type (Immunomodulators, Monoclonal Antibodies, Oncolytic Viral Therapies & Cancer Vaccines), Service Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症免疫治疗药物发现外包市场价值为16亿美元，预计2024年将达到18.4亿美元，复合年增长率为15.59%，到2030年将达到44.1亿美元，预计将达到1000万美元。

在癌症免疫治疗的药物发现外包中，药物开发的各个阶段，从研发到临床试验，皆委託给外部专业机构。该策略帮助製药公司简化流程、降低成本，并利用他们内部不具备的先进技术和专业知识。癌症免疫治疗科学知识和技术的快速发展推动了药物发现外包的需求，这需要公司不断创新以保持竞争力。主要研究应用包括单株抗体、查核点抑制剂、癌症疫苗、细胞疗法和细胞激素，最终用途广泛，包括製药公司、生技公司、研究机构和委外研发机构(CRO)。

主要市场统计
基准年[2023] 16亿美元
预测年份 [2024] 18.4亿美元
预测年份 [2030] 44.1亿美元
复合年增长率（%） 15.59%

根据市场洞察，癌症患者数量的增加、免疫疗法的创新以及个人化医疗的推动等趋势推动了外包产业的发展。外包对于处理药物发现和开发过程的复杂性并有效满足监管要求至关重要。旨在共享专业知识和资源的策略联盟和联合研究也在增加。然而，资料安全问题、合作伙伴之间不同的品质标准以及严格的法规环境等挑战可能会阻碍成长。此外，在保持开放沟通的同时不断审查成本和收益的需要也会影响市场动态。

创新的机会在于先进的生物资讯学，以加速目标识别和增强的生物模拟技术，以优化药物测试步骤。使用人工智慧和机器学习进行药物发现的预测和优化具有巨大的成长潜力。市场的性质变得越来越适应性，重点是具有客製化监管和开发策略的利基治疗方法和产品。公司可以透过利用这些技术进步并促进与学术机构和 CRO 的伙伴关係来受益。在这些情况下，投资安全、强大的资料管理工具和透明的沟通管道对于克服市场挑战和利用成长机会至关重要。

市场动态：快速发展的癌症免疫疗法药物发现外包市场的关键市场洞察

供需的动态交互作用正在改变癌症免疫疗法药物发现外包市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球癌症发生率上升
    • 提高医生和病人对免疫治疗的认识
    • 增加对癌症治疗开发的投资
  • 市场限制因素
    • 药物开发和治疗成本高昂
  • 市场机会
    • 增加有效癌症免疫疗法开发的临床试验
    • 增加与製药公司的 CDMO 合作伙伴关係
  • 市场挑战
    • 严格的政府法规和指导方针

波特五力：引领癌症免疫疗法药物发现外包市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解癌症免疫疗法药物发现外包市场的外部影响

外部宏观环境因素在塑造癌症免疫疗法药物发现外包市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解癌症免疫治疗药物发现外包市场的竞争状况

癌症免疫疗法药物发现外包市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵供应商在癌症免疫治疗药物发现外包市场的绩效评估

FPNV定位矩阵是评估癌症免疫疗法药物发现外包市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製癌症免疫疗法药物发现外包市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对癌症免疫治疗药物发现外包市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率正在上升
      • 提高医生和病人对免疫治疗的认识
      • 增加对癌症治疗开发的投资
    • 抑制因素
      • 药物开发和治疗高成本
    • 机会
      • 增加临床试验以开发有效的癌症免疫疗法
      • 扩大与製药公司的 CDMO 合作
    • 任务
      • 严格的政府法规和指导方针
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以癌症类型分類的癌症免疫治疗药物发现外包市场

  • 胸部
  • 冒号
  • 头部和颈部
  • 肺
  • 恶性黑色素瘤
  • 卵巢
  • 胰臟
  • 摄护腺

第七章按药物类型分類的癌症免疫治疗药物发现外包市场

  • 免疫调节剂
  • 单株抗体
  • 溶瘤病毒疗法和癌症疫苗

第八章癌症免疫治疗药物发现外包市场：依服务类型

  • 基于细胞的检测
  • 铅筛检与表征
  • 目标识别与检验

第九章北美和南美癌症免疫疗法药物发现外包市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区癌症免疫治疗药物发现外包市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲癌症免疫疗法药物发现外包市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Inc.
  • Dalton Pharma Services
  • DiscoverX Corporation
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • Genscript Biotech Corporation
  • HD Biosciences Co., Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Jubilant Life Sciences Limited
  • Labcorp
  • Oncodesign Precision Medicine Opm SA
  • Personalis, Inc.
  • Promega Corporation
  • STC Biologics Inc.
  • TCG Lifesciences Pvt. Limited
  • WuXi AppTec Co., Ltd.
Product Code: MRR-205091A88709

The Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 1.60 billion in 2023, expected to reach USD 1.84 billion in 2024, and is projected to grow at a CAGR of 15.59%, to USD 4.41 billion by 2030.

Cancer immunotherapy drug discovery outsourcing involves delegating various stages of drug development-from research and development to clinical trials-to specialized external entities. This strategy helps pharmaceutical companies streamline processes, reduce costs, and access advanced technologies and expertise that might not be available in-house. The necessity of outsourcing in drug discovery is driven by the rapid evolution of scientific knowledge and technology related to cancer immunotherapy, where companies need to innovate continuously to remain competitive. Applications primarily include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, cell therapies, and cytokines, with end-use sectors spanning pharmaceutical and biotechnology firms, research institutes, and contract research organizations (CROs).

KEY MARKET STATISTICS
Base Year [2023] USD 1.60 billion
Estimated Year [2024] USD 1.84 billion
Forecast Year [2030] USD 4.41 billion
CAGR (%) 15.59%

Market insights reveal that the outsourcing sector is buoyed by trends such as the escalation in cancer cases, innovations in immunotherapy treatments, and the push for personalized medicine. Outsourcing becomes essential to handle complexities in drug discovery and development processes, as well as to address regulatory demands efficiently. An increase in strategic alliances and collaborations can also be seen, aiming to pool expertise and resources. However, challenges such as data security concerns, variability in quality standards across partners, and stringent regulatory environments can impede growth. Moreover, the necessity to continuously scrutinize costs and benefits while maintaining open communication can affect market dynamics.

Innovation opportunities lie in advanced bioinformatics-which expedites target identification-and enhanced biosimulation techniques that optimize drug testing phases. Leveraging artificial intelligence and machine learning for predictions and optimization in drug discovery offers significant growth potential. The nature of the market is becoming increasingly adaptive, focusing on niche therapies and products with tailored regulatory and development strategies. Companies would benefit from leveraging these technological advancements and fostering partnerships with academia and CROs, where investing in secure, robust data management tools and transparent communication channels will be crucial to navigate market challenges and capitalize on growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Immunotherapy Drug Discovery Outsourcing Market

The Cancer Immunotherapy Drug Discovery Outsourcing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer globally
    • Increasing awareness regarding immunotherapy among physicians and patients
    • Increasing investments for the development of cancer therapies
  • Market Restraints
    • High cost of drug development and treatment
  • Market Opportunities
    • Rise in clinical trials for development of efficient cancer immunotherapy
    • Increasing CDMO collaborations with pharmaceutical companies
  • Market Challenges
    • Stringent government regulations and guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Immunotherapy Drug Discovery Outsourcing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Immunotherapy Drug Discovery Outsourcing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Immunotherapy Drug Discovery Outsourcing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Immunotherapy Drug Discovery Outsourcing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Immunotherapy Drug Discovery Outsourcing Market

A detailed market share analysis in the Cancer Immunotherapy Drug Discovery Outsourcing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Immunotherapy Drug Discovery Outsourcing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Immunotherapy Drug Discovery Outsourcing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Immunotherapy Drug Discovery Outsourcing Market

A strategic analysis of the Cancer Immunotherapy Drug Discovery Outsourcing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Drug Discovery Outsourcing Market, highlighting leading vendors and their innovative profiles. These include BPS Bioscience, Inc., Celentyx Ltd., Charles River Laboratories International, Inc., Covance, Inc., Crown Bioscience, Inc., Curia Inc., Dalton Pharma Services, DiscoverX Corporation, Eurofins Scientific, Evotec SE, Explicyte, Genscript Biotech Corporation, HD Biosciences Co., Ltd., Horizon Discovery Group PLC, ImmunXperts SA, Jubilant Life Sciences Limited, Labcorp, Oncodesign Precision Medicine Opm SA, Personalis, Inc., Promega Corporation, STC Biologics Inc., TCG Lifesciences Pvt. Limited, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Immunotherapy Drug Discovery Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Breast, Colorectal, Head and Neck, Lung, Melanoma, Ovarian, Pancreatic, and Prostate.
  • Based on Drug Type, market is studied across Immunomodulators, Monoclonal Antibodies, and Oncolytic Viral Therapies & Cancer Vaccines.
  • Based on Service Type, market is studied across Cell-based Assays, Lead Screening & Characterization, and Target Identification & Validation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Increasing awareness regarding immunotherapy among physicians and patients
      • 5.1.1.3. Increasing investments for the development of cancer therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in clinical trials for development of efficient cancer immunotherapy
      • 5.1.3.2. Increasing CDMO collaborations with pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and guidelines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast
  • 6.3. Colorectal
  • 6.4. Head and Neck
  • 6.5. Lung
  • 6.6. Melanoma
  • 6.7. Ovarian
  • 6.8. Pancreatic
  • 6.9. Prostate

7. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Immunomodulators
  • 7.3. Monoclonal Antibodies
  • 7.4. Oncolytic Viral Therapies & Cancer Vaccines

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Cell-based Assays
  • 8.3. Lead Screening & Characterization
  • 8.4. Target Identification & Validation

9. Americas Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. BPS Bioscience, Inc.
  • 2. Celentyx Ltd.
  • 3. Charles River Laboratories International, Inc.
  • 4. Covance, Inc.
  • 5. Crown Bioscience, Inc.
  • 6. Curia Inc.
  • 7. Dalton Pharma Services
  • 8. DiscoverX Corporation
  • 9. Eurofins Scientific
  • 10. Evotec SE
  • 11. Explicyte
  • 12. Genscript Biotech Corporation
  • 13. HD Biosciences Co., Ltd.
  • 14. Horizon Discovery Group PLC
  • 15. ImmunXperts SA
  • 16. Jubilant Life Sciences Limited
  • 17. Labcorp
  • 18. Oncodesign Precision Medicine Opm SA
  • 19. Personalis, Inc.
  • 20. Promega Corporation
  • 21. STC Biologics Inc.
  • 22. TCG Lifesciences Pvt. Limited
  • 23. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BREAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEAD AND NECK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OVARIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PANCREATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRAL THERAPIES & CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD SCREENING & CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023